213Bi-anti MISRII antibodies (Institut de Recherche en Cancerologie de Montpellier)

N/A

Report date: 2025/01/26 15:54:11

Base Information

Drug Name213Bi-anti MISRII antibodies (Institut de Recherche en Cancerologie de Montpellier)

Drug Alias Name213Bi-16F12 mAb

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateRadiation-emitting products

Mechanisms of ActionAnti-Mullerian hormone receptor II modulators

TargetsAnti-Mullerian hormone receptor II

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInstitut De Recherche En Cancérologie De Montpellier (Ircm)

China Registration ClassN/A

Develop Information

Active CompaniesInstitut De Recherche En Cancérologie De Montpellier (Ircm)

Inactive CompaniesN/A

Active IndicationsOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A